左心耳封堵术后单药抗凝与双联抗血小板治疗效果相当
Is It Over for DAPT After Left Atrial Appendage Closure?
SIMPLAAFY 试验显示,左心耳封堵术后6个月,单药非维生素K口服抗凝药物或阿司匹林单药治疗与双联抗血小板治疗效果相当,但单药治疗出血风险较低。
研究显示单药抗凝与双联抗血小板治疗在左心耳封堵术后6个月效果相当,为临床决策提供依据。
— Antithrombotic monotherapy worked at least as well at 6 months
by Nicole Lou, Senior Staff Writer, MedPage Today
November 4, 2026 • 3 min read
Antithrombotic monotherapy was similar to dual antiplatelet therapy (DAPT) for 6-month outcomes after left atrial appendage (LAA) closure, the SIMPLAAFY trial showed.
The incidence rate of combined all-cause death, stroke, systemic embolism, or major bleeding at 6 months was 5.1% with reduced-dose non-vitamin K oral anticoagulants (NOACs), 3.3% with aspirin alone, and 6.9% with DAPT, reported Saibal Kar, MD, of Los Robles Hospital and Medical Center in Thousand Oaks, California, at the Transcatheter Cardiovascular Therapeutics annual conference hosted by the Cardiovascular Research Foundation.
Statistically, the strategy of reduced-dose NOACs was at least as good as DAPT (risk ratio [RR] 0.75, 95% CI 0.48-1.18), as was aspirin alone (RR 0.49, 95% CI 0.29-0.82).
"These findings support the simplification of antithrombotic management after uncomplicated LAA [closure] and may be individualized according to competing bleeding and device thrombosis risks and patient preferences," Kar said.
The study was simultaneously published in JAMA.
Among the secondary analyses in the trial, there was no excess stroke at 6 months with the aspirin or NOAC monotherapy regimens. However, bleeds alone gave both an edge over DAPT, while low-dose NOAC therapy stood out for a relatively low incidence of device-related thrombus (DRT) at 45 days (0.9% vs 3.4% with DAPT and 2.7% with aspirin).
As it stands, standard practice varies widely for antithrombotic therapy after LAA closure on account of a "lack of legitimate evidence" for guidance, said session discussant Mohamad Alkhouli, MD, of the Mayo Clinic in Rochester, Minnesota.
"Aspirin seems to emerge a winner," Alkhouli suggested, based on SIMPLAAFY, while he noted that "the jury is still out" for NOACs.
Complicating the picture is the ANDES trial, which found that after LAA closure, short-term NOACs were no better than DAPT at preventing DRT at 60 days, and were associated with even more DRTs at 1 year (5.2% vs 2.3%, P=0.154).
Kar said these data gave him pause on making a blanket recommendation for NOACs after LAA closure.
Meanwhile, 12-month results from SIMPLAAFY are still pending.
"The fact is that we really didn't know what to do with these patients," said Kar. "What we will do beyond 1 year, I don't know."
SIMPLAAFY included patients with nonvalvular atrial fibrillation who had the Watchman FLX Pro LAA occluder successfully implanted. The investigators randomized 1,857 patients 1:1:1 to aspirin 81 to 100 mg alone, initial DAPT for 6 months (followed by aspirin thereafter), or initial reduced-dose NOACs -- 2.5-mg apixaban (Eliquis) twice daily or 10-mg rivaroxaban (Xarelto) daily -- for 3 months (followed by aspirin thereafter).
Across the three study groups, mean age was 76 years, 43% were women, mean CHA2DS2-VASc score was 4.2, and mean HAS-BLED bleeding risk score was 2.6.
Acute events through 7 days were rare in general. Rates of clinically relevant nonmajor bleeding were 1.0% with aspirin alone, 1.6% with DAPT, and 1.5% with low-dose NOACs; major bleeding rates were 0.2%, 0.5%, and 0.2%, respectively.
The proportion of participants adhering to their assigned medications (for 80% or more days) was 87.9% with aspirin alone, 76.8% with DAPT, and 85.3% with reduced-dose NOACs. "Both monotherapy treatments were better tolerated than DAPT," Kar noted.
A subgroup analysis indicated that people ages 75 and older had disproportionately better outcomes on aspirin (RR 0.34, 95% CI 0.18-0.64) or reduced-dose NOACs (RR 0.53, 95% CI 0.31-0.93).
LAA imaging at 45 days suggested no differences in the Watchman device seal across groups.
Kar stressed that only uncomplicated LAA occluder implants were included in the trial, limiting the generalizability of the findings. Some high-risk populations were also excluded (e.g., those with severe kidney disease, recent stroke, myocardial infarction, or major bleeding).
Of note, there was no prespecified comparison of the two monotherapy arms.
来源:MedPage Today · medpagetoday.com